Sign In
Buy NBSE
$0.378
+0 (+0%)
At Close: Aug 09, 2024
4 Best Vision Insurance Companies for 2020 • Benzinga
11:08am, Wednesday, 02'nd Oct 2019
Selecting the best vision insurance can seem complex. Benzinga's financial experts compare plans to help you make the best choice in 2020.
NeuBase Therapeutics to Present at the Chardan 3rd Annual Genetic Medicines Conference
01:08pm, Thursday, 26'th Sep 2019
PITTSBURGH, Sept. 26, 2019 -- NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing next-generation antisense therapies to.
Micro-Cap Rodeo Investor Conference October in Austin Texas
03:25pm, Saturday, 21'st Sep 2019
Company lineup is filling up fast with 50 good names in the microcap markets, as well as some great private and Pre-IPO companies AUSTIN, TX / ACCESSWIRE / September 19, 2019 / The MicroCap Rodeo's in
NeuBase Therapeutics Hosting Key Opinion Leader Meeting on Huntington's Disease and PATrOL™-Enabled Therapy on September 16th
12:39pm, Monday, 09'th Sep 2019
NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing next-generation antisense therapies to address genetic diseases, today announced that
NeuBase Therapeutics Reports Financial Results for the Fiscal Third Quarter of 2019
08:05pm, Wednesday, 14'th Aug 2019
Completed two financings in July 2019 totaling approximately $14 million in gross proceeds with participation from institutional investors including Greenlight Capital.
NeuBase Therapeutics to Ring the NASDAQ Closing Bell Today
12:00pm, Wednesday, 07'th Aug 2019
NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” and the “Company”), a biotechnology company developing next generation antisense therapies to address genetic diseases, announced today tha
NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing next-generation antisense therapies to address genetic diseases, today announced the
NeuBase Therapeutics Appoints Danith Ly, Ph.D. as Chief Scientific Officer
12:00pm, Wednesday, 24'th Jul 2019
NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing next-generation antisense therapies to address genetic diseases, today announced the
NeuBase Therapeutics Initiates Trading on NASDAQ Under Ticker Symbol “NBSE”
02:20pm, Monday, 15'th Jul 2019
NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” and the “Company”), a biotechnology company developing next generation antisense therapies to address genetic diseases, announced today tha
Travel insurance for pre-existing medical conditions made easy
11:21pm, Wednesday, 29'th Oct 2014
Need travel insurance for a pre-existing condition? Compare travel insurance and find cover for pregnancy, diabetes, cancer and more ✓
SKS Microfinance stock plunge faces regulatory probe
02:43pm, Sunday, 08'th May 2011
A steep plunge of 20% in SKS Microfinance shares has come under the regulatory lens for possible breach of insider trading norms or hammering by a bear cartel.
